Table 1.

Prevalence of elevated liver enzymes from different COVID-19 studies.

Reference	Group	Patients (n)	% of patients with abnormal liver test
[2]	Severe	85	ALT (82.3), AST (75.3), GGT (72.3), ALP (12.2)
	Non-severe	233	ALT (52.2), AST (26.9), GGT (39.1), ALP (10.5)
[12]	Hospitalized	99	ALT (28), AST (35)
[5]	Hospitalized	1099	ALT (21.3), AST (22.2)
[3]	Severe	13	62
	Non-severe	28	25
[6]	Hospitalized	81	53
[13]	Severe	36	Not known
	Non-severe	102	Not known
[14]	Hospitalized	62	16.1
[15]	Survivors	20	30
	Non-survivors	32	28
[4]	Severe	30	ALT (16.7), AST (26.7)
	Mild	61	ALT (8.2), AST (16.4)

Severe: patients admitted in the intensive care unit (ICU).